Terms: = Liver cancer AND TNFAIP3, TNFA1P2, 7128, ENSG00000118503, OTUD7C, MGC138687, MGC104522, A20, MGC138688, P21580 AND Treatment
13 results:
1. Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma.
Su CW; Teng W; Lin PT; Jeng WJ; Chen KA; Hsieh YC; Chen WT; Ho MM; Hsieh CH; Wang CT; Chai PM; Lin CC; Lin CY; Lin SM
Cancer Med; 2023 Mar; 12(6):7077-7089. PubMed ID: 36468578
[TBL] [Abstract] [Full Text] [Related]
2.
Fan L; Liao W; Chen Z; Li S; Yang A; Chen MM; Liu H; Liu F
Aging (Albany NY); 2022 May; 14(9):3801-3812. PubMed ID: 35504024
[TBL] [Abstract] [Full Text] [Related]
3. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
[TBL] [Abstract] [Full Text] [Related]
4. a20 targets PFKL and glycolysis to inhibit the progression of hepatocellular carcinoma.
Feng Y; Zhang Y; Cai Y; Liu R; Lu M; Li T; Fu Y; Guo M; Huang H; Ou Y; Chen Y
Cell Death Dis; 2020 Feb; 11(2):89. PubMed ID: 32015333
[TBL] [Abstract] [Full Text] [Related]
5. A Family With a20 Haploinsufficiency Presenting With Novel Clinical Manifestations and Challenges for treatment.
Hautala T; Vähäsalo P; Kuismin O; Keskitalo S; Rajamäki K; Väänänen A; Simojoki M; Säily M; Pelkonen I; Tokola H; Mäkinen M; Kaarteenaho R; Jartti A; Hautala N; Kantola S; Jackson P; Glumoff V; Saarela J; Varjosalo M; Eklund KK; Seppänen MRJ
J Clin Rheumatol; 2021 Dec; 27(8):e583-e587. PubMed ID: 31977656
[TBL] [Abstract] [Full Text] [Related]
6. Emerging role of zinc finger protein a20 as a suppressor of hepatocellular carcinoma.
Yi PS; Shu Y; Bi WX; Zheng XB; Feng WJ; He LY; Li JS
J Cell Physiol; 2019 Dec; 234(12):21479-21484. PubMed ID: 31134613
[TBL] [Abstract] [Full Text] [Related]
7. [Effect of a20 gene induced silencing on the biological behaviors of human nasopharyngeal carcinoma cell].
Liu F; Xie WB; Zhou LY; Liu YH; Fang WY; Yao KT
Zhonghua Yi Xue Za Zhi; 2018 Jun; 98(24):1956-1961. PubMed ID: 29996290
[No Abstract] [Full Text] [Related]
8. Effects of DLC1 Deficiency on Endothelial Cell Contact Growth Inhibition and Angiosarcoma Progression.
Sánchez-Martín D; Otsuka A; Kabashima K; Ha T; Wang D; Qian X; Lowy DR; Tosato G
J Natl Cancer Inst; 2018 Apr; 110(4):390-399. PubMed ID: 29202196
[TBL] [Abstract] [Full Text] [Related]
9. Downregulation of a20 increases the cytotoxicity of IFN-γ in hepatocellular carcinoma cells.
Yin L; Fang Z; Shen NJ; Qiu YH; Li AJ; Zhang YJ
Drug Des Devel Ther; 2017; 11():2841-2850. PubMed ID: 29033545
[TBL] [Abstract] [Full Text] [Related]
10. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
[TBL] [Abstract] [Full Text] [Related]
11. Targeting a20 enhances TRAIL-induced apoptosis in hepatocellular carcinoma cells.
Dong B; Lv G; Wang Q; Wei F; Bellail AC; Hao C; Wang G
Biochem Biophys Res Commun; 2012 Feb; 418(2):433-8. PubMed ID: 22285182
[TBL] [Abstract] [Full Text] [Related]
12. miR-29c targets tnfaip3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma.
Wang CM; Wang Y; Fan CG; Xu FF; Sun WS; Liu YG; Jia JH
Biochem Biophys Res Commun; 2011 Aug; 411(3):586-92. PubMed ID: 21763284
[TBL] [Abstract] [Full Text] [Related]
13. Mitogenic and anti-proliferative activity of a lectin from the tubers of Voodoo lily (Sauromatum venosum).
Singh Bains J; Singh J; Kamboj SS; Nijjar KK; Agrewala JN; Kumar V; Kumar A; Saxena AK
Biochim Biophys Acta; 2005 May; 1723(1-3):163-74. PubMed ID: 15788150
[TBL] [Abstract] [Full Text] [Related]
